Compare ATLX & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | TTRX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 116.0M |
| IPO Year | 2012 | N/A |
| Metric | ATLX | TTRX |
|---|---|---|
| Price | $4.43 | $3.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | ★ 322.0K | 16.8K |
| Earning Date | 05-08-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,491.00 | N/A |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $2.57 |
| 52 Week High | $8.25 | $5.98 |
| Indicator | ATLX | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 38.27 |
| Support Level | $4.32 | $2.94 |
| Resistance Level | $5.25 | $3.92 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 36.82 | 28.98 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.